Solventum publishes Q3 2026 earnings call transcript
SOLV•Solventum raised its adjusted EPS guidance to $7.20-$7.30 and expects organic sales growth near the top of its 2.5%-3% range. Quarterly sales fell 7% to $1.95 billion, reflecting ERP-related order reversals, while normalized organic growth was approximately 4%.
1. Updated outlook
At its Q3 fiscal 2026 earnings call on November 5, CEO Bryan Hanson and CFO Wayde McMillan said adjusted EPS guidance had risen to $7.20-$7.30 from $7.10-$7.20. The company expects organic sales growth near the top of its 2.5%-3% range.
2. Sales and business plans
Quarterly sales fell 7% to $1.95 billion, reflecting ERP-related order reversals; normalized organic growth was approximately 4%. Management is considering a spin-off or sale of Health Information Systems, which carries approximately 400 basis points of anticipated operating margin dilution. A renegotiated 3M supply agreement eliminates a potential 100-basis-point gross margin headwind, and management expects operating margin expansion in 2027.
